Proactively investing to prepare for commercialization
Our 63,000 sqft manufacturing facility in Indianapolis, Indiana, is expected to be operational by the end of 2023. Indianapolis has a central location in the United States, allowing for ground shipments to a large number of cities within two days of manufacture. Additionally, Indianapolis houses the second-largest FedEx hub in the world, which specializes in shipping radiopharmaceutical drugs.
The facility is being built to have the capacity to support manufacturing for clinical development and commercialization, if approved, of our pipeline programs. We are also investing in capabilities to produce Actinium-225 from this facility.
